Sec Form 13G Filing - Venrock Healthcare Capital Partners III L.P. @ Cidara Therapeutics Inc.

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Link

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

Cidara Therapeutics, Inc.

(Name of Issuer)

Common stock, $0.0001 par value per share

(Title of Class of Securities)

171757206

(CUSIP Number)

November 26, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 171757206

Page 2 of 17

1.	Names of Reporting Persons Venrock Healthcare Capital Partners III, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)

Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

(2)

Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of pre-funded warrants (the “Pre-Funded Warrants”) held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The Pre-Funded Warrants contain a provision (the “Beneficial Ownership Blocker”) which precludes exercise of the Pre-Funded Warrants to the extent that, following exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2024; (ii) 3,892,274 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on November 26, 2024 (the “Private Placement”); and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 3 of 17

1.	Names of Reporting Persons VHCP Co-Investment Holdings III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)

(2)

Consists of (i) 132,317 shares of Common Stock and 62,791 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners III, L.P.; (ii) 13,247 shares of Common Stock and 6,286 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by VHCP Co-Investment Holdings III, LLC; and (iii) 620,159 shares of Common Stock and 294,297 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by Venrock Healthcare Capital Partners EG, L.P. The share numbers reported above represent the maximum number of shares of Common Stock issuable upon exercise of the Pre-Funded Warrants as a result of the Beneficial Ownership Blocker.

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 4 of 17

1.	Names of Reporting Persons Venrock Healthcare Capital Partners EG, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)

(2)

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 5 of 17

1.	Names of Reporting Persons VHCP Management III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)

(2)

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 6 of 17

1.	Names of Reporting Persons VHCP Management EG, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)

Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II I, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G.

(2)

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 7 of 17

1.	Names of Reporting Persons Shah, Nimish
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)

(2)

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 8 of 17

1.	Names of Reporting Persons Koh, Bong
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States

Number of

Beneficially

Owned by

Each

Reporting

Person With

Sole Voting Power

Shared Voting Power

1,129,097 (2)

Sole Dispositive Power

Shared Dispositive Power

1,129,097 (2)

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,129,097 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 9.99% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)

(2)

(3)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 2 above.

CUSIP No. 171757206

Page 9 of 17

Item 1.
	(a)	Name of Issuer Cidara Therapeutics, Inc.

	(b)	Address of Issuer’s Principal Executive Offices 6310 Nancy Ridge Drive, Suite 101 San Diego, CA 92121

Item 2.
	(a)	Name of Person Filing Venrock Healthcare Capital Partners III, L.P. VHCP Co-Investment Holdings III, LLC Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC VHCP Management EG, LLC Nimish Shah Bong Koh

	(b)	Address of Principal Business Office or, if none, Residence

		New York Office:	Palo Alto Office:

		7 Bryant Park	3340 Hillview Avenue
		23rd Floor	Palo Alto, CA 94304
		New York, NY 10018

	(c)	Citizenship

		All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

	(d)	Title of Class of Securities Common Stock, $0.0001 par value

	(e)	CUSIP Number 171757206

CUSIP No. 171757206

Page 10 of 17

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	Not applicable

Item 4.	Ownership

	(a)	Amount beneficially owned:

				Venrock Healthcare Capital Partners III, L.P.	1,129,097	(1)
				VHCP Co-Investment Holdings III, LLC	1,129,097	(1)
				Venrock Healthcare Capital Partners EG, L.P.	1,129,097	(1)
				VHCP Management III, LLC	1,129,097	(1)
				VHCP Management EG, LLC	1,129,097	(1)
				Nimish Shah	1,129,097	(1)
				Bong Koh	1,129,097	(1)

	(b)	Percent of class:

				Venrock Healthcare Capital Partners III, L.P.	9.99%	(2)
				VHCP Co-Investment Holdings III, LLC	9.99%	(2)
				Venrock Healthcare Capital Partners EG, L.P.	9.99%	(2)
				VHCP Management III, LLC	9.99%	(2)
				VHCP Management EG, LLC	9.99%	(2)
				Nimish Shah	9.99%	(2)
				Bong Koh	9.99%	(2)

	(c)	Number of shares as to which the person has:

		(i)	Sole power to vote or to direct the vote:

				Venrock Healthcare Capital Partners III, L.P.	0
				VHCP Co-Investment Holdings III, LLC	0
				Venrock Healthcare Capital Partners EG, L.P.	0
				VHCP Management III, LLC	0
				VHCP Management EG, LLC	0
				Nimish Shah	0
				Bong Koh	0

		(ii)	Shared power to vote or to direct the vote:

				Venrock Healthcare Capital Partners III, L.P.	1,129,097	(1)
				VHCP Co-Investment Holdings III, LLC	1,129,097	(1)
				Venrock Healthcare Capital Partners EG, L.P.	1,129,097	(1)
				VHCP Management III, LLC	1,129,097	(1)
				VHCP Management EG, LLC	1,129,097	(1)
				Nimish Shah	1,129,097	(1)
				Bong Koh	1,129,097	(1)

CUSIP No. 171757206

Page 11 of 17

(iii)	Sole power to dispose or to direct the disposition of:

		Venrock Healthcare Capital Partners III, L.P.	0
		VHCP Co-Investment Holdings III, LLC	0
		Venrock Healthcare Capital Partners EG, L.P.	0
		VHCP Management III, LLC	0
		VHCP Management EG, LLC	0
		Nimish Shah	0
		Bong Koh	0

(iv)	Shared power to dispose or to direct the disposition of:

		Venrock Healthcare Capital Partners III, L.P.	1,129,097	(1)
		VHCP Co-Investment Holdings III, LLC	1,129,097	(1)
		Venrock Healthcare Capital Partners EG, L.P.	1,129,097	(1)
		VHCP Management III, LLC	1,129,097	(1)
		VHCP Management EG, LLC	1,129,097	(1)
		Nimish Shah	1,129,097	(1)
		Bong Koh	1,129,097	(1)

(1)

VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

(2)

This percentage is calculated based upon the sum of: (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 3,892,274 shares of Common Stock issued in the Private Placement; and (iii) 363,374 shares issuable upon the exercise of the Pre-Funded Warrants described in Footnote 1 above.

Item 5.	Ownership of Five Percent or Less of a Class

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not applicable

CUSIP No. 171757206

Page 12 of 17

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

	Not applicable

Item 8.	Identification and Classification of Members of the Group

	Not applicable

Item 9.	Notice of Dissolution of Group

	Not applicable

Item 10.	Certification

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

CUSIP No. 171757206

Page 13 of 17

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 4, 2024

Venrock Healthcare Capital Partners III, L.P.		Venrock Healthcare Capital Partners EG, L.P.

By:	VHCP Management III, LLC	By:	VHCP Management EG, LLC
Its:	General Partner	Its:	General Partner

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

VHCP Co-Investment Holdings III, LLC

By:	VHCP Management III, LLC
Its:	Manager

By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther
	Its: Authorized Signatory

VHCP Management III, LLC		VHCP Management EG, LLC

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

Nimish Shah

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

Bong Koh

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

CUSIP No. 171757206

Page 14 of 17

EXHIBITS

A:	Joint Filing Agreement

B:	Power of Attorney for Nimish Shah

C:	Power of Attorney for Bong Koh

CUSIP No. 171757206

Page 15 of 17

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Cidara Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 4^th day of December 2024.

Venrock Healthcare Capital Partners III, L.P.		Venrock Healthcare Capital Partners EG, L.P.

By:	VHCP Management III, LLC	By:	VHCP Management EG, LLC
Its:	General Partner	Its:	General Partner

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

VHCP Co-Investment Holdings III, LLC

By:	VHCP Management III, LLC
Its:	Manager

By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther
	Its: Authorized Signatory

VHCP Management III, LLC		VHCP Management EG, LLC

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

Nimish Shah

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

Bong Koh

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

CUSIP No. 171757206

Page 16 of 17

EXHIBIT B

POWER OF ATTORNEY FOR NIMISH SHAH

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to:

(i)

prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act ) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder; and

(ii)

take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of undersigned, is not assuming, nor is Venrock assuming, any of the undersigned’s responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned’s holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact, or (c) until such attorney-in-fact shall no longer be employed by VR Management, LLC (or its successor).

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4^th day of December 2024.

/s/ Nimish Shah

CUSIP No. 171757206

Page 0;17 of 17

EXHIBIT C

POWER OF ATTORNEY FOR BONG KOH

(i)

(ii)

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4^th day of December 2024.

/s/ Bong Koh

Sec Form 13G Filing - Venrock Healthcare Capital Partners III L.P. filing for Cidara Therapeutics Inc. (CDTX) - 2024-12-04